OPEN

Author Correction: A phase I clinical trial for [^{131}I] meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma

Hiroshi Wakabayashi, Anri Inaki , Kenichi Yoshimura, Toshinori Murayama, Yasuhito Imai, Tetsuya Higuchi, Megumi Jinguji, Tohru Shiga & Seigo Kinuya

Correction to: *Scientific Reports* <https://doi.org/10.1038/s41598-019-43880-6>, published online 20 May 2019

The original version of this article contained an error in the 95% confidence intervals calculated for the second and third courses of ^{131}I -mIBG.

As a result, in the Results section under the subheading ‘Response evaluation’,

“Eight patients received a second course of ^{131}I -mIBG therapy. The scintigraphic response in the second course was 5% in CR (1/20), 10% in PR (2/20), 20% in SD (4/20), 5% in PD (1/20), and 60% in unknown (12/20). The response rate was 15% (95% CI: 6.0–61.0%).”

now reads:

“Eight patients received a second course of ^{131}I -mIBG therapy. The scintigraphic response in the second course was 5% in CR (1/20), 10% in PR (2/20), 20% in SD (4/20), 5% in PD (1/20), and 60% in unknown (12/20). The response rate was 15% (95% CI: 3.2–37.9%).”

“Three patients received a third course of ^{131}I -mIBG therapy. There were three patients with PR (15%) and 17 patients with unknown (85%) in the scintigraphic response. The response rate was 15% (95% CI: 29.2–100.0%).”

now reads:

“Three patients received a third course of ^{131}I -mIBG therapy. There were three patients with PR (15%) and 17 patients with unknown (85%) in the scintigraphic response. The response rate was 15% (95% CI: 3.2–37.9%).”

The original Article has been corrected.

Published online: 19 January 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022